Cargando…

PD-1 is a marker of activation on tumor infiltrating NK cells in head and neck cancer

Detalles Bibliográficos
Autores principales:	Concha-Benavente, Fernando, Srivastava, Raghvendra M, Kansy, Benjamin, Ferris, Robert L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4652519/ http://dx.doi.org/10.1186/2051-1426-3-S2-P398

Ejemplares similares

Anti-EGFR targeted monoclonal antibody isotype influences anti-tumor immunity in head and neck cancer patients
por: Trivedi, Sumita, et al.
Publicado: (2015)

IFNγ-induced PD-L1 expression is JAK2 but not JAK1 dependent and its inhibition enhances NK-cetuximab mediated ADCC of HNSCC cells
por: Concha-Benavente, Fernando, et al.
Publicado: (2014)

A Phase Ib study of neoadjuvant immune biomarker modulation with cetuximab and motolimod in head and neck cancer (HNC)
por: Ferris, Robert L, et al.
Publicado: (2015)

Anti-PD-1 mAb pre-radiotherapy (RT) loading dose and fractionated RT induce better tumor-specific immunity and tumor shrinkage than sequential administration in an HPV+ head and neck cancer model
por: Srivastava, Raghvendra M, et al.
Publicado: (2015)

STING activation enhances cetuximab-mediated NK cell activation and DC maturation and correlates with HPV(+) status in head and neck cancer
por: Lu, Shanhong, et al.
Publicado: (2018)

Level of PD-1 expression on CD8+ T cells influence prognosis and respond to PD-1 therapy in a murine model
por: Kansy, Benjamin A, et al.
Publicado: (2015)

STAT1 contributes to HLA class I upregulation and CTL reactivity after anti-EGFR mAb cetuximab therapy in head and neck cancer patients
por: Srivastava, Raghvendra M, et al.
Publicado: (2013)

EGFR-mediated tumor immunoescape: The imbalance between phosphorylated STAT1 and phosphorylated STAT3
por: Concha-Benavente, Fernando, et al.
Publicado: (2013)

TIM-3(+) T cells are not exhausted but activated cells in the tumor microenvironment
por: Jie, Hyun-Bae, et al.
Publicado: (2013)

Nimotuzumab Induces NK Cell Activation, Cytotoxicity, Dendritic Cell Maturation and Expansion of EGFR-Specific T Cells in Head and Neck Cancer Patients
por: Mazorra, Zaima, et al.
Publicado: (2017)

Anti-EGFR mAb cetuximab therapy increases T cell receptor (TCR) diversity in the peripheral blood and focuses TCR richness in the tumor microenvironment
por: Kansy, Benjamin A, et al.
Publicado: (2015)

PD-L1 is preferentially expressed on CD44+ tumor-initiating cells in head and neck squamous cell carcinoma
por: Lee, Yunqin, et al.
Publicado: (2014)

OX40 and other immunoregulatory molecules are highly expressed on tumor infiltrating lymphocytes in oral, head and neck squamous cell carcinoma
por: Montler, Ryan, et al.
Publicado: (2014)

Differential expression of PD-1 and Tim-3 marks activation versus exhaustion status of T cells in the tumor microenvironment
por: Li, Jing, et al.
Publicado: (2014)

PD-1/SHP-2 negatively regulate Tc1/Th1 phenotypic responses and activation of T cells in the tumor microenvironment
por: Li, Jing, et al.
Publicado: (2014)

Cetuximab ameliorates suppressive phenotypes of myeloid antigen presenting cells in head and neck cancer patients
por: Li, Jing, et al.
Publicado: (2015)

Assessment of the tumor immune-environment in patients with head and neck cancer
por: Feng, Zipei, et al.
Publicado: (2015)

Modulation of immune cell infiltrate with sunitinib to improve anti-PD1 therapy in preclinical tumor model
por: Rayman, Patricia, et al.
Publicado: (2015)

Utilizing quantitative immunohistochemistry for relationship analysis of tumor microenvironment of head and neck cancer patients
por: Feng, Zipei, et al.
Publicado: (2014)

PD-1 blockade upregulate TIM-3 expression as a compensatory regulation of immune check point receptors in HNSCC TIL
por: Shayan, Gulidanna, et al.
Publicado: (2015)

Targeting uroporphyrinogen decarboxylase for head and neck cancer treatment
por: Ito, Emma, et al.
Publicado: (2013)

An evaluation of autologous tumor-reactive TIL generation from head and neck squamous cell cancers
por: Mougdil, Tarsem, et al.
Publicado: (2015)

Active8: a randomized, double-blind, placebo-controlled study of chemotherapy plus cetuximab in combination with TLR8 agonist VTX-2337 in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN)
por: Ferris, Robert L, et al.
Publicado: (2014)

Phase III, randomized, open-label study of durvalumab (MEDI4736) monotherapy, or durvalumab + tremelimumab, versus standard of care (SoC), in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): eagle
por: Ferris, Robert L, et al.
Publicado: (2015)

Anti-tumor effects of anti-PD-L1 therapy in an orthotopic bladder tumor model
por: Lyon, Amanda, et al.
Publicado: (2014)

The bidirectional tumor - mesenchymal stromal cell interaction promotes the progression of head and neck cancer
por: Kansy, Benjamin A, et al.
Publicado: (2014)

P24. Aviscumine enhances NK- cytotoxicity against tumor cells
por: Gamerith, G, et al.
Publicado: (2014)

Siglec-7/-9 ligands shield tumor cells from NK cell attack
por: Jandus, Camilla, et al.
Publicado: (2013)

Clinical scale zinc finger nuclease (ZFN)-driven gene-editing of PD-1 in tumor infiltrating lymphocytes (TIL) for the potential treatment of metastatic melanoma
por: Beane, Joal D, et al.
Publicado: (2014)

EGFR signaling suppresses type 1 cytokine-induced T-cell attracting chemokine secretion in head and neck cancer
por: Ma, Wenbo, et al.
Publicado: (2018)

Cancer stem cells in head and neck squamous cell carcinoma
por: Karamboulas, Christina, et al.
Publicado: (2013)

Anti-tumor characteristics of radiation-induced tumor-infiltrating neutrophils
por: Takeshima, Tsuguhide, et al.
Publicado: (2014)

Characterization of tumor infiltrated cells in mouse model
por: Liou, Yae-Huei, et al.
Publicado: (2015)

Reversing EGFR Mediated Immunoescape by Targeted Monoclonal Antibody Therapy
por: Concha-Benavente, Fernando, et al.
Publicado: (2017)

Radiation therapy and vaccination against tumor-specific EGFRvIII effectively clears tumors in a murine model of head and neck squamous cell carcinoma
por: Uhde, Lauren, et al.
Publicado: (2015)

Prognostic markers of the outcome in severe head injuries
por: Sarafidou, P, et al.
Publicado: (2006)

MicroRNAs and cell proliferation in head and neck squamous cell carcinoma
por: Andreghetto, Flavia M, et al.
Publicado: (2013)

Multiplex immunohistochemistry for immune profiling of HPV-associated head and neck cancer
por: Tsujikawa, Takahiro, et al.
Publicado: (2015)

Promoting NK cell trafficking to improve therapeutic effect of NK cell therapy on osteosarcoma
por: Yang, Yuanzheng, et al.
Publicado: (2015)

IL-12 stimuli during ex vivo expansion not only prevents the upregulation of PD1 on tumor infiltrating adoptively transferred T cells but also on endogenous TILs which results in effective tumor regression
por: Diaz-Montero, C Marcela, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_rdrt4v66aqnav0umn5adrj0qpe